Michael Davidson to Young Adult
This is a "connection" page, showing publications Michael Davidson has written about Young Adult.
Connection Strength
0.953
-
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers. Am J Cardiovasc Drugs. 2025 Sep; 25(5):693-702.
Score: 0.096
-
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants. Drug Saf. 2025 Sep; 48(9):993-1004.
Score: 0.095
-
Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression. Schizophr Res. 2020 01; 215:352-356.
Score: 0.064
-
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018 Jul - Aug; 12(4):898-907.e2.
Score: 0.058
-
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
Score: 0.055
-
Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks. Regul Toxicol Pharmacol. 2014 Dec; 70 Suppl 2:S143-57.
Score: 0.046
-
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
Score: 0.042
-
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):1B-3B.
Score: 0.040
-
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012 Nov-Dec; 6(6):573-84.
Score: 0.038
-
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun; 166(6):675-82.
Score: 0.031
-
Refractive errors and schizophrenia. Schizophr Res. 2009 Feb; 107(2-3):238-41.
Score: 0.030
-
Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized? Schizophr Bull. 2026 Jan 16; 52(1).
Score: 0.025
-
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 Aug 19; 68(1):e116.
Score: 0.024
-
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. Arterioscler Thromb Vasc Biol. 2025 Jul; 45(7):1310-1315.
Score: 0.024
-
Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria. Schizophr Res. 2024 09; 271:246-252.
Score: 0.022
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
Score: 0.022
-
Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort. Eur Neuropsychopharmacol. 2020 03; 32:131-135.
Score: 0.016
-
Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
Score: 0.016
-
Understanding the association between advanced paternal age and schizophrenia and bipolar disorder. Psychol Med. 2020 02; 50(3):431-437.
Score: 0.015
-
Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun; 79(3).
Score: 0.015
-
A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis. Am J Psychiatry. 2018 04 01; 175(4):351-358.
Score: 0.014
-
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2017 Oct; 42(5):815-825.
Score: 0.014
-
No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. Am J Cardiovasc Drugs. 2017 Jun; 17(3):251-260.
Score: 0.014
-
Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol. 2017 May - Jun; 11(3):739-748.
Score: 0.014
-
Has deinstitutionalization affected inpatient suicide? Psychiatric inpatient suicide rates between 1990 and 2013 in Israel. Schizophr Res. 2016 May; 173(1-2):75-8.
Score: 0.013
-
Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA Psychiatry. 2016 Jan; 73(1):48-55.
Score: 0.012
-
Risk of completed suicide in 89,049 young males assessed by a mental health professional. Eur Neuropsychopharmacol. 2016 Feb; 26(2):341-349.
Score: 0.012
-
The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces together. Biol Psychiatry. 2015 Dec 01; 78(11):786-93.
Score: 0.012
-
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
Score: 0.011
-
Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study. Genet Epidemiol. 2013 Nov; 37(7):751-7.
Score: 0.010
-
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 Jun; 147(1):132-139.
Score: 0.010
-
Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res. 2012 Dec; 142(1-3):129-36.
Score: 0.010
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.009
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
Score: 0.009
-
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec; 115(2-3):97-103.
Score: 0.008
-
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
Score: 0.008